June 17, 2019
4 min watch
Save

VIDEO: Venetoclax-obinutuzumab combination improves outcomes in treatment-naive chronic lymphocytic leukemia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — Rod Humerickhouse, MD, PhD, asset strategy leader for venetoclax at AbbVie, spoke with HemOnc Today at ASCO Annual Meeting about results of the phase 3 CLL14 study.

The results, presented at ASCO, showed the combination of venetoclax (Venclexta; AbbVie, Genentech) and obinutuzumab (Gazyva, Genentech) extended PFS and induced higher rates of complete response compared with a commonly used regimen of obinutuzumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia.

The combination also demonstrated an effect on minimal residual disease that had never before been reported in CLL, Humerickhouse said.

“This really does support the idea that you can treat patients for a fixed duration, stop therapy and have long sustained progression-free intervals, which both patients and physicians value,” he told HemOnc Today.

Humerickhouse also provided an overview of the company’s pipeline and the key research focus areas over the next year and beyond. – by Mark Leiser